Aligning intelligence…
Aligning intelligence…
AI Consulting · Automation · Development
You want faster reads, less documentation load, and quicker discovery. We help Malta and EU health and life sciences teams put AI to work across diagnostic imaging, clinical notes, and drug discovery, keeping it compliant and auditable from day one, together.
AI in healthcare has moved past pilots into daily use across the EU, and radiology is the most common way in. Systems flag findings such as lung nodules, diabetic retinopathy, and pneumonia. Triage tools push urgent studies up the worklist and cut reporting backlogs. In clinical documentation, NLP turns free-text notes into structured codes (ICD-10/ICD-11, SNOMED CT) and hands time back to clinicians. In life sciences, protein-structure prediction (AlphaFold-class models) has compressed parts of early-stage discovery, and AI-assisted variant interpretation lifts geneticist throughput and consistency on sequencing workloads.
For SMEs and mid-market organisations, the hard part is rarely the technology. It is governance. Health data is special-category data, so the rules on consent, automated decisions, and patient safety are strict, and software that acts as a medical device still needs CE marking. We treat that as a design input, not an afterthought. The specifics (GDPR Article 9 and 22 conditions, the EU AI Act high-risk duties under Articles 9 to 15 with a 2 August 2027 application date for product-embedded systems, and MDR/IVDR conformity assessment) are all covered in the FAQs below, and we build to them from the first sprint. The result is AI you can defend to a regulator and an auditor.
Governance & compliance
Malta sits inside the same EU pathways with a clear local route. The MDIA is the lead market-surveillance authority and runs the national AI regulatory sandbox, and the Information and Data Protection Commissioner remains the data-protection regulator. That makes Malta a practical home base for compliance-by-design. Paired with the wider EU single market and Mediterranean research talent, including the University of Malta's genomics and molecular-medicine groups, it is an equally strong base for European life sciences SMEs. We build the governance in from the first sprint, not after, and we ship in weeks, not months.
AI that flags findings in radiology and retinal images, including lung nodules, diabetic retinopathy, and pneumonia. It supports clinician judgement, never replaces it, with human-in-the-loop review built in for high-risk classification.
NLP that turns free-text clinical notes into structured codes (ICD-10/ICD-11, SNOMED CT). You cut documentation time and administrative load, and a clinician reviews before anything is finalised.
AI that reorders clinical worklists so urgent cases surface first. You shorten reporting backlogs and time-to-read for time-critical findings.
Protein-structure prediction and AI-assisted molecular modelling that shorten early candidate identification. It complements experimental validation rather than replacing it.
AI-assisted analysis of sequencing results that raises geneticist throughput and consistency, with full audit trails for clinical sign-off.
NLP over electronic health records that surfaces outcome patterns and identifies eligible patients for clinical trials. You accelerate enrolment while respecting GDPR and the Clinical Trials Regulation (536/2014).
If your AI is itself a medical device or a safety component of one, almost certainly. Article 6(1) of Regulation 2024/1689 makes it high-risk, triggering risk-management, data-governance, human-oversight, transparency, and post-market-monitoring duties under Articles 9 to 15. For these product-embedded systems the application date is 2 August 2027, and these duties sit alongside, not instead of, MDR/IVDR conformity assessment.
Health data is special-category data under GDPR (Regulation 2016/679), so you need a specific Article 9 condition to process it: explicit consent, or a healthcare/medical-diagnosis basis. Article 22 also restricts decisions based solely on automated processing where they significantly affect a patient, which is why we design clinician-in-the-loop review into every diagnostic or decision-support workflow.
Yes. Software as a medical device falls under MDR (2017/745) or IVDR (2017/746) and still needs CE marking and notified-body conformity assessment, where capacity bottlenecks remain a real constraint. The EU AI Act layers on top of that regime rather than replacing it, so we plan both pathways together from the start to avoid certification surprises.
The Ministry for Health oversees healthcare delivery, while the MDIA is Malta's lead market-surveillance authority for the EU AI Act under the Artificial Intelligence Regulations (L.N. 226 of 2025) and runs the national AI regulatory sandbox. The Information and Data Protection Commissioner (L.N. 227 of 2025) is the data-protection regulator and market-surveillance authority for specific domains such as biometrics, together giving Malta-based teams a clear route into the wider EU market.
From first strategy to live systems, we cover the full path for Healthcare & Life Sciences teams, no need to hire a full AI team up front.
A five-minute read on where Healthcare & Life Sciences teams like yours stand before committing to a build.